666 inentingen Prepandrix Biodefence stockpile H5N1 'Novel flu virus' Dodelijke aspecten

Een belangrijk puntje;

- vraag en kijk wie er toestemming heeft gegeven voor deze producten.

- van wie de patenten en de aandelen van de diverse bedrijven zijn

- roep uw arts, medisch specialist of consultatiearts ter verantwoording

- schrijf iedereen wat er gaande is !

- benader media de gemeente, het RIVM, het NVI, uw consultatiebureau, uw drogist, uw apotheek. Maak gebruik van deze vragen alsmede van de vragenlijst op onze pagina over vaccinaties Link Vraag het vanuit uw hart, oprecht, rechtstreeks en duidelijk !

- Beroep u naar instanties toe op uw recht op informatie. Verzoek om, en als dat niet snel genoeg gaat; Eis openheid. Vraag om de complete stukken in het kader van de freedom of information act danwel openbaarheid van bestuur, het burgelijk wetboek, de rechten van de mens en de rechten van uw kind, alsmede uw aller gezondheid en herstel en structurele verbetering van uw waarschijnlijk zwaar verstoorde relatie met overheid en bedrijfsleven.

- Weet u wat u dagelijks koopt en van wie ? Link Waar geeft u uw invloed aan ?

666 bio chip mark Link

FROM 2005! Proposed new legislation S 666!

S. 666 Biological, Chemical, and Radiological Weapons Countermeasures Research Act

Coaxing Pharma Out of the Gate Drug Discovery & Development - June 01, 2005

http://www.rollitup.org/politics/217503-s-666-biological-chemical-radiological.html

Ted Agres Deputy managing editor, Washington Times

Expect a major fight this year in Congress over plans to expand on Project BioShield. Proposed new legislation would grant a raft of new incentives, such as patent extensions, liability protections, and additional tax credits, to pharmaceutical and biotech companies that develop countermeasures against bioterrorism agents.

Not surprisingly, the biotech and branded drug industries generally support the proposed incentives, whereas generic drug makers oppose them. But there appears to be enough support from all quarters to pass at least some incentives this year, particularly protection against liability exposure for companies developing bioterror therapies. Major drug manufacturers say they need these and other measures before embarking on the costly and risky process of developing countermeasures for such agents as anthrax, smallpox, plague, and botulism. Generic drug manufacturers say some of the proposed incentives, especially patent term extensions, will delay access to more affordable medicines and increase prescription drug costs.

"It is outrageous that under the guise of homeland security, the [branded pharmaceuticals] industry is seeking patent extensions for everyday medicines at the expense of consumers, especially seniors and the uninsured—individuals who need affordable, life-saving generic medicines the most," said Kathleen Jaeger, president of the Generic Pharmaceutical Association (GPhA), a trade association in Washington, D.C.

Two new pieces of legislation, both called BioShield II, would expand on the original Project BioShield, which was signed into law last July. While the earlier legislation guaranteed $5.6 billion to develop and stockpile new vaccines and countermeasures, industry executives have been largely sitting on the sidelines, awaiting additional measures to protect their companies from liability and to encourage more R&D through tax credits and patent term extensions.

"Large pharmaceutical companies have so far not been interested in BioShield because of fear of being sued" if they make a vaccine or drug that has adverse health effects, said Frank Rapoport, managing partner at McKenna Long & Aldridge, a law firm representing drug and biotech companies seeking government contracts.

Many of those hoped-for measures are included in new legislation being pushed by senators Joseph Lieberman (D-Conn.) and Orrin Hatch (R-Utah). Much of their bill is based on legislation they introduced last year but which failed to gain traction in Congress. That earlier bill, the Biological, Chemical, and Radiological Weapons Countermeasures Research Act (S. 666), included tax credits, intellectual property incentives, and liability protections.

The S. 666 bill also offered companies developing bioterror countermeasures patent extensions equal to the regulatory review period for their primary products. Companies would also receive tax credits to pursue countermeasures R&D, an important provision because not every new drug will make money, making patent extension less attractive for some.

Perhaps most controversial, the bill also offered a "wild card" extension of two years on an unrelated patent. So, if Pfizer successfully developed a BioShield vaccine for the government, it could receive a two-year patent extension on an unrelated drug of its choice. The new version of the bill includes a watered down version of the wild card provision, Rapoport said. Several big pharmas have already backed away from the wild card provision and others are not taking a position on the matter, preferring to focus instead on liability protection and guaranteed purchase commitments from the government.

Another version of BioShield II is in the works. While the wild card patent extension is not included in S. 3, another patent provision is nearly as contentious. This provision would allow the government to reward manufacturers that develop a countermeasure from existing products. Up to two years additional market exclusivity could be granted for a product that is developed as a countermeasure to compensate the company for directing their resources in this direction.

"This type of incentive will encourage manufacturers to step forward in a crisis and will help them recoup their losses from diverting their research and manufacturing efforts from more profitable products," Gregg said. But the GPhA's Jaeger opposes the provision. "Commonly prescribed drugs to treat headaches, nausea, and depression would be eligible for patent extensions with minimal testing performed by the brand manufacturer," she said. One area where the generics and branded industries agree is support for additional liability lawsuit protections to companies developing bioterror countermeasures. In an emergency, these products could be made available without having gone through clinical trials or other human subjects testing, with safety and efficacy data derived primarily from animal trials. Existing law is "woefully inadequate to address the practical realities of potential litigation facing providers of countermeasures," Gregg said. Under both versions of BioShield II, liability protections would be extended to new bioterror-related products.

"It's not unreasonable that in five years we'll see 10 to 15% of the defense budget dedicated to public health and bioweapons," Rapoport predicts. "We're not talking about just $5.6 billion from BioShield. If the defense budget is $400 billion, we're talking $40 to $60 billion and the creation of a new industry."

Building this strong biodefense sector is imperative, Gregg said. "We have an obligation to be prepared for the worst threat. Maybe that next [bioterror] attack will never come. Or maybe it will come tomorrow. But we have an obligation to make sure that we have done all we can to be prepared and protected if our luck runs out," Gregg said.

In religion and politics, people's beliefs and convictions are in almost every case gotten at second hand,

and without examination. Mark Twain

Senate Bills - 108th Congress

http://olpa.od.nih.gov/tracking/senate_bills/session1/s-666.asp

"S. 666—Biological, Chemical, and Radiological Weapons Countermeasures Research Act

On March 19, 2003, Senator Joseph Lieberman (D-CT) introduced S. 666, the Biological, Chemical, and Radiological Weapons Countermeasures Research Act. Provisions would authorize the Director of NIH to award partnership challenge grants to promote joint ventures between the Agency, its grantees, and for-profit biotechnology, pharmaceutical, and medical device industries for the development of countermeasures and research tools. The Director would be required to issue regulations within 90 days of enactment of the bill to implement the awarding of these grants. Authorized would be $200 million for each of the FYs 2004 through 2008. S. 666 was referred to the Senate Committee on Finance.

Legislative Update (August 2003): Biological, Chemical, Radiological, and Nuclear Defense"

S. 666—Biological, Chemical, and Radiological Weapons Countermeasures Research Act

S. 666 would authorize the Director of NIH to award partnership challenge grants to promote joint ventures between the Agency, its grantees, and for-profit biotechnology, pharmaceutical, and medical device industries for the development of biological, chemical, radiological, and nuclear countermeasures and research tools. The Director would be required to issue regulations within 90 days of the enactment of the bill to implement the awarding of these grants. S. 666 would also authorize $200 million for each of the fiscal years (FYs) 2004 through 2008. In addition to NIH-related provisions, the bill would provide a number of incentives, tax credits, antitrust exemptions, and exclusive licensing protections to encourage industry to engage in countermeasures research and development. Bron : Link

Een ernstig stuk daarbij is:

The S. 666 Biological, Chemical, and Radiological Weapons Countermeasures Research Act, 2003, paved way for government funding of Baxter, Novartis and GSK in bioweapons research

http://birdflu666.wordpress.com/2009/07/23/s-666-biological-chemical-and-radiological-weapons-countermeasures-research-act-of-2003/

By birdflu666

Senate bill S. 666, the Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2003, gave incentives to private industry in the USA to conduct research into bioweapons, allegedly to fill gaps in the US biodefense procurement programs. John Rockefeller was on a key Senate finance committee reviewing the bill which channelled amounts of government money into private biotechnology, pharmaceutical companies such as Baxter in order to develop bioweapons.

The Lieberman-Hatch bill S. 666 introduced incentives for companies to detect and weaponise viruses and also find “diagnostics” against viruses.

The Rockefeller family is also one of the biggest sponsors of WHO.

Also, Arlene Rockefeller, CFA, is an Executive Vice President of State Street Global Advisors and is the Global Equities CIO.

State Street Global Advisors is the largest institutional/mutual fund investment firms owning Baxter.

Baxter International Inc: Majority Institutional Ownership Ownership Information

Shares Outstanding 605.00 Mil

Institutional Ownership (%) 83.24

Top 10 Institutions (%) 29.30

Mutual Fund Ownership (%) 2.64

5%/Insider Ownership (%) .36

Float (%) 99.64

Ownership Activity

Description # of Holders Shares

Total Positions 877 503,624,352

New Positions 92 0

Soldout Positions 177 0

Net Position Change -174 -14,197,458

Buyers 395 48,125,760

Sellers 569 -62,323,216

advertisement

______________________________________________________________

Institution Name Shs Held Shs Chg %Chg $Chg* %Out %Port Rpt Date

State Street Global Advisors (US) 24,740,248 -1,343,238 -5.2 -130,618,512 4.1 0.4 03-31-09

Barclays Global Investors, N.A. 24,373,600 -846,249 -3.4 -103,115,920 4.0 0.4 03-31-09

Fidelity Management & Research 21,648,076 -7,284,945 -25.2 -441,706,144 3.6 0.4 03-31-09

Vanguard Group, Inc. 20,649,172 625,238 3.1 -15,432,030 3.4 0.4 03-31-09

AllianceBernstein L.P. 17,845,732 -1,229,416 -6.4 -108,178,784 3.0 0.8 03-31-09

Jennison Associates LLC 14,516,432 -1,330,325 -8.4 -105,696,064 2.4 2.0 03-31-09

Goldman Sachs Asset Management (US) 13,858,386 3,026,445 27.9 129,342,816 2.3 1.2 03-31-09

T. Rowe Price Associates, Inc. 13,792,483 126,386 0.9 -25,915,160 2.3 0.5 03-31-09

State Farm Insurance Companies 12,975,694 0 0.0 -30,752,394 2.1 2.0 03-31-09

Capital World Investors 12,811,500 4,525,622 54.6 212,164,832 2.1 0.3 03-31-09

Relational Investors LLC 11,089,644 800,031 7.8 16,591,205 1.8 16.6 03-31-09

INTECH Investment Management LLC 9,702,750 -301,537 -3.0 -39,154,884 1.6 1.3 03-31-09

Barrow, Hanley, Mewhinney & Strauss, Inc. 8,001,019 -3,263,540 -29.0 -193,855,520 1.3 1.3 03-31-09

TIAA-CREF 7,745,417 1,144,562 17.3 42,980,440 1.3 0.5 03-31-09

Capital Guardian Trust Company 7,643,189 -491,339 -6.0 -44,445,216

--

I don't see H1N1 listed as part of the stockpiles

However H1N1 vaccine ingredients were ordered as part of the bio defense stockpile

http://www.infectioncontroltoday.com/hotnews/h1n1-vaccine-ingredients.html

HHS Purchases Additional H1N1 Vaccine Ingredients 07/13/2009

HHS Secretary Kathleen Sebelius announced today that the department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus.

“We recognize that preparedness is shared responsibility between federal, tribal, state, local governments, private organizations and individuals. We are doing our part to be as prepared as possible for the impact that this infectious disease could have on our country,” Sebelius said. “Vaccines may serve an important role in that preparedness. The action we are taking today will provide flexibility in a future immunization program, if a program is recommended.”

The funds will be used to place additional orders for bulk H1N1 antigen and adjuvant on existing contracts with Sanofi Pasteur, MedImmune, GlaxoSmithKline and Novartis. The vaccine ingredients will be as part of the pandemic stockpile, for use if a vaccination campaign is necessary.

Antigen is the active ingredient in a vaccine that causes the human body’s immune system to develop antibodies that help fight an invading virus. Depending on the results of clinical studies, adjuvant could be added to a vaccine to boost the immune system’s response and potentially reduce the amount of antigen necessary for the body to recognize and fight a virus.

In May, Sebelius directed approximately $1 billion to be used for the development of a vaccine and for clinical studies to determine dose level and assess the safety and effectiveness of potential vaccines. The Biomedical Advanced Research and Development Authority (BARDA) in the HHS Office of the Assistant Secretary for Preparedness and Response established the existing contracts with these companies in 2004 as part of the National Strategy for Pandemic Influenza.

-http://www.govtrack.us/congress/bill.xpd?bill=s108-666 -

The bill never went anywhere during this year. Was it resurrected under another bill in another year?

EU Recommendation 666

"Recommendation 666" is an actual document of the Western European Union saying that it will be the "military muscle" of the EU. The WEU is made up of 10 full member nations (As is the anti-christ's one world government) and also establishes the senior ranking High Representative who has the power to call a council at any time, and to execute (quote) "emergency powers"

See Also

• Resolution 666
• Seat 666
• Javier Solana

Please do not believe me, use Google and call my bluf ..

http://www.assembly-weu.org/en/index.php --> (put 666 in search box)

I was finally able to get to a computer to cut and paste this list of US666 and EU666 products. I have screenshots of the searches on my blog: http://remixxworld.blogspot.com/2009/07/list-of-us666-eu666-biodefense.html

US666 List of Biodefense Stockpile Products

Anthrax Vaccine, rDNA [rPA; Bacillus anthracis protective antigen vaccine, recombinant]

Anthrax Vaccine, rDNA/Emergent [Bacillus anthracis protective antigen, recombinant]

Botulinum Toxoids [Pentavalent Botulinum Toxoids - Botulinum Toxoids ABCDE]

Influenza H5N1 Vaccine Products [Pandemic Influenza vaccine, surface antigen, inactivated; influenza virus H5N1, inactivated, vaccine; bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine; ]

Influenza Vaccine, H5N1/GSK [Prepandrix; Pandemrix - influenza virus H5N1, inactivated, vaccine, with AS03 adjuvant; bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine]

Influenza Vaccine, H5N1/MedImmune [influenza virus H5N1, inactivated, intranasal, recombinant, cell cultured vaccine; CAIV-T (H5N1); FluMist (H5N1); bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine]

Influenza Vaccine, H5N1/Novartis [Pandemic Influenza vaccine, surface antigen, inactivated - Focetria; influenza virus H5N1 vaccine, inactivated; Pandemic Influenza vaccine, surface antigen, inactivated; H5N1 MPH]

Influenza Vaccine, H5N1/Sanofi [influenza virus H5N1, inactivated, vaccine; bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine; influenza virus A/Indonesia (H5N1, clade 2) vaccine]

Smallpox Vaccine Products [Vaccinia virus, live [vaccine against variola virus]]

Smallpox Vaccine/Wyeth [Smallpox Vaccine - Dryvax; vaccinia virus live vaccine [vaccine against variola virus]]

Smallpox vaccine/Aventis [Smallpox Vaccine, Dried, Calf Lymph Type - Wetvax; live vaccinia virus vaccine against variola virus]

Smallpox vaccine/MRC-5 [Vaccinia virus, live, MRC-5; ACAM1000; CCSV - smallpox vaccine]

Smallpox vaccine/Vero [Vaccinia virus, live, Vero cell cultured; ACAM2000 - smallpox vaccine]

Smallpox Vaccine/MVA [Vaccinia virus, live, Modified Vaccinia Ankara strain; Imvamune; MVA smallpox vaccine - MVA-BN; MVA3000]

EU666 List of Biodefense Stockpile Products

Anthrax Vaccine [Anthrax Vaccine Adsorbed - BioThrax; AVA; Bacillus anthracis vaccine]

Influenza H5N1 Vaccine Products [Pandemic Influenza vaccine, surface antigen, inactivated; influenza virus H5N1, inactivated, vaccine; bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine; ]

Influenza Vaccine, H5N1/GSK [Prepandrix; Pandemrix - influenza virus H5N1, inactivated, vaccine, with AS03 adjuvant; bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine]

Smallpox Vaccine/Elstree [Elstree-BN; live vaccinia virus vaccine against variola virus]

Smallpox Vaccine/MVA [Vaccinia virus, live, Modified Vaccinia Ankara strain; Imvamune; MVA smallpox vaccine - MVA-BN; MVA3000]

Swine flu could hit up to 40 percent in US 25 juli 2009

The World Health Organization says as many as 2 billion people could become infected in the next two years — nearly a third of the world population. The estimates look at potential impacts in a two-year period because past flu pandemics have occurred in waves over more than one year. Swine flu has been an escalating concern in Britain and some other European nations, where the virus' late arrival has grabbed attention and some officials at times have sounded alarmed. In an interview Friday, the WHO's flu chief told the AP the global epidemic is still in its early stages.

"Even if we have hundreds of thousands of cases or a few millions of cases ... we're relatively early in the pandemic," Keiji Fukuda said at WHO headquarters in Geneva.

Er is nog meer !!!

" http://www.davidicke.com/content/view/25191

Excerpts:

Baxter International said it will be shipping swine flu vaccine worldwide by the end of July and the potential profits are fantastic; but this is not primarily about money. It about a long-planned mass-culling of the human population.

We are told that the drug companies and the World Health Organization have been working at fever pitch to develop a vaccine for the 'new' swine flu strain known as H1N1, but ... wait for it ... Baxter International filed a patent for the H1N1 vaccine on August 28th 2008.

Click here to read ... PDF: http://www.theoneclickgroup.co.uk/documents/vaccines/Baxter%20Vaccine%20Patent%20Application.pdf

Baxter Vaccine Patent Application US 2009/0060950 A1 says:

'... In particular preferred embodiments the composition or vaccine comprises more than one antigen ... such as influenza A and influenza B in particular selected from of one or more of the human H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7 subtypes, of the pig flu H1N1, H1N2, H3N1 and H3N2 subtypes, of the dog or horse flu H7N7, H3N8 subtypes or of the avian H5N1, H7N2, H1N7, H7N3, H13N6, H5N9, H11N6, H3N8, H9N2, H5N2, H4N8, H10N7, H2N2, H8N4, H14N5, H6N5, H12N5 subtypes.'

The patent was published in March 2009, a month before the virus was released in Mexico in April, but it was filed seven months before this 'new strain' was officially known about. It is the most blatant set-up you could ever see.

The patent includes the following ingredients and toxicity warning:

'Suitable adjuvants can be selected from mineral gels, aluminium hydroxide, surface active substances, lysolecithin, pluronic polyols, polyanions or oil emulsions such as water in oil or oil in water, or a combination thereof. Of course, the selection of the adjuvant depends on the intended use. E.g. toxicity may depend on the destined subject organism and can vary from no toxicity to high toxicity.'

The excellent work of people like the American researcher and author, Patrick Jordan, have exposed the unfolding plan to kill vast numbers of people through engineered viruses and vaccines. He says that they have long perfected vaccines that switch off the human immune system and US troops have often been used as guinea pigs.

Patrick Jordan's research uncovers a three-vaccine system that the Illuminati have developed. The first inoculation turns off white blood cells (the immune system); the second injects viruses; and the third switches the immune system on again.

In the middle period viruses are expanding around the body, but the person doesn't feel sick because the immune system is not fighting them. When the immune system kicks in again it unleashes such an assault on the virus cocktail that it kills the body.

This is known as a cytokine storm http://en.wikipedia.org/wiki/Cytokine_storm when the immune system is so overwhelmed that it sends too many antibodies at the same time to infected areas of the body and the body kills itself.

It is also the case that the World Health Organisation has asked for live swine flu virus to be in the vaccine and it is quite possible that they will expand and maybe increase the strength of the virus through the vaccine. The WHO website says:

'In view of the anticipated limited vaccine availability at global level and the potential need to protect against "drifted" strains of virus, SAGE recommended that promoting production and use of vaccines such as those that are formulated with oil-in-water adjuvants and live attenuated influenza vaccines was important.'

Onderstaand gegeven was mij al vanuit verschillende bronnen bekend, maar nog nooit had ik daaarvoor de documenten kunnen vinden. Bron Link

Dankzij Patrick Jordan en Jane Bürgermeister heb ik die nu kunnen vinden, zie hier beneden.

WHO Memoranda from 1972 prove three shots mandated by US

government for “swine flu” vaccine designed to be killer

July 8, 2009 by birdflu666

Please make sure to listen to vaccine experts Dr Rebecca Carley and Patrick Jordan, discuss two key memorandums from WHO, discovered by Patrick Jordan, which prove WHO has intentionally created the three-shot killer vaccine that people in the USA and other countries could soon be forced to take on “What’s Ailing America?” this Saturday at 3 PM EST

www.republicbroadcasting.org Link

Dr. Patricia Jordan, DVM internationally recognized expert on Vaccine Induced Diseases in Animals and Humans will also be joining in the discussion on what is in the three shots “flu” to be produced by

companies like Baxter and mandated by President Obama.

1972 WHO Bulletin 47, No 2 Memoranda #1 and #2 technically outline the ability to create

biological weapons in the form of vaccines that:

1) First totally disable the Immune System.

2) Load every cell of the Victim’s body up with Infection.

3) Switch the Immune System on causing the host to kill themselves in a Cytokine Storm.

One, Two, Three, Dead.

Op deze link zijn de beide documenten te downloaden. Link

Scroll naar beneden tot je vindt:

http://www.pubmedcentral.nih.gov/tocrender.fcgi?iid=169484

Memoranda

Virus-associated immunopathology: animal models and implications for human disease: 1.

Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated

immunologic injury

Bull World Health Organ. 1972; 47(2): 257–264.

PMCID: PMC2480894

| Summary | Page Browse | PDF–1.2M |

Virus-associated immunopathology: animal models and implications for human disease: 2.

Cell-mediated immunity, autoimmune diseases, genetics, and implications for clinical research

Bull World Health Organ. 1972; 47(2): 265–274

PMCID: PMC2480896

| Summary | Page Browse | PDF–1.5M |

These WHO Memoranda describe the three-stage impact of the three “shots” many people will be forced to take this fall to allegedly treat a virus that WHO also helped create and release.

Many thanks to Patrick Jordan, Patricia Jordan and Dr Carley who have uncovered this crucial piece of evidence of WHO’s long-term genocidal intentions that could stand in any court of law because

these memorandums give the best and fullest explanation WHO’s and affilated labs (such as the CDC) current activities, such as their patenting of the most lethal bird flu viruses, their sending that virus to

Baxter’s subsidiary in Austria, which weaponised it and sent out 72 kilos to 16 labs in four countries almost triggering a global pandemic.

For every crime, there needs to be motive, an indication that it was deliberate, planned. The WHO memorandums provide the evidence of just that deliberate, long-term planning to kill people by

weakening their immune system by use of the first vaccine, injecting a live virus into their body by a second, and creating a cytokine storm using squalene in a third.

Het adjuvans op oliebasis, squaleen, zit ook in Cervarix...

Het is ook gebruikt in de antraxvaccins voor de militairen in Golfoorlog-1.

Bij onderzoek met dieren gebruiken wetenschappers kinkhoestvaccin om bij dieren hersenontstekingen te veroorzaken, en olie-adjuvantia zoals squaleen en "Freund's (in)complete

adjuvant" om onmiddellijk auto-immuun schade te veroorzaken. Dergelijke acties zijn aan regels gebonden: het is namelijk te wreed...

Maar voor ons gelden die regels kennelijk niet!

Denk eraan, blijven ademen, en verhef jezelf in onvoorwaardelijke liefde!

Wat kunt u nog meer lezen met betrekking tot dit onderwerp ?

666, geloof Biodefence en GlaxoSmithKline Link Oorspronkelijke bron : Link Zie wat er gaande is in Engeland en Amerika !!!!

De huidige inentingen moeten eigenlijk opgevat worden als een Biodifence middel. Daarmee zouden ze de code 666 krijgen !!!

Een nadere uitleg hieronder is afkomstig van de : "

Case in point, GlaxoSmithKline's designation of Flu stockpiles in their "Regulatory/Status Index". Glaxo’s pandemic influenza vaccine is characterized by regulatory authorities as a substance that needs to be stockpiled in the EU’s and USA’s bio defense stockpiles. I'll let the last bit of terminology they used slide for now.

Nog meer informatie :

Bekijk het ondersaande overzicht goed ! H5N1 gaat dit over de vogelgriep. U kunt o.a. zien dat de aanvraag bij de EU in Mei 2008 is gedaan.

Regulatory/Status Index:

EU666 Bio defense stockpile

US666 Bio defense stockpile

This classification by regulatory authorities underscores fears that the pandemic flu vaccines, which contain toxic adjuvants, are indeed actually bio weapons, designed to cause death and injury. How could anyone not reach that conclusion after all the evidence to that end presented to this point, and now this revelation?

Furthermore, the Glaxo vaccine is categorized as having "controlled or government distribution in the EU and USA" only. Below is the entry for the Glaxo pandemic influenza vaccine on a biopharma database. Scroll down to see the Regulatory/Status Index.